De novo NFKBIA variants within the N-terminal hotspot: consistent immunophenotype and divergent clinical presentations
-
By
-
Rui Gan
-
Guangzhao Li
-
Lina Zhou
-
Li Wang
-
Rongxin Dai
-
Xuemei Tang
-
Junfeng Wu
-
Yanjun Jia
-
Qing Zhou
-
Xiaodong Zhao
-
Yunfei An
-
June 5, 2026
-
Clinical Scorecard: Novel NFKBIA Variants in the N-terminal Region: Consistent Immunological Profiles with Variable Clinical Outcomes
At a Glance
| Category | Detail |
|---|
| Condition | N-terminal IκBα gain-of-function disease |
| Key Mechanisms | Impaired TNF-α-induced IκBα degradation and defective lymphocyte maturation |
| Target Population | Patients with germline monoallelic gain-of-function variants in NFKBIA |
| Care Setting | Clinical immunology and genetic diagnosis |
Key Highlights
- Four unrelated patients with de novo heterozygous NFKBIA variants were studied.
- Clinical severity varied from recurrent infections to severe multisystem disease.
- All patients exhibited ectodermal abnormalities and a consistent immune phenotype.
- Markedly delayed TNF-α-induced IκBα degradation was observed in patient PBMCs.
- Distinct alleles showed convergent immunologic phenotypes despite clinical heterogeneity.
Guideline-Based Recommendations
Diagnosis
- Whole-exome sequencing for molecular diagnosis of NFKBIA variants.
Management
- Clinical and immunological phenotyping for tailored patient management.
Monitoring & Follow-up
- Regular follow-up for infection and immune function assessment.
Risks
- Increased susceptibility to bacterial, fungal, and opportunistic infections.
Patient & Prescribing Data
Patients with heterozygous NFKBIA variants presenting with immunodeficiency.
Management strategies must be based on clinical evidence.
Clinical Best Practices
- Conduct comprehensive immunologic profiling in patients with NFKBIA variants.
- Consider genetic counseling for affected families.
Related Resources & Content
